Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Rating) – Equities research analysts at Cantor Fitzgerald dropped their FY2023 earnings estimates for Lucid Diagnostics in a report issued on Wednesday, March 15th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will earn ($1.19) per share for the year, down from their prior estimate of ($0.87). The consensus estimate for Lucid Diagnostics’ current full-year earnings is ($1.19) per share.
Separately, Needham & Company LLC cut their target price on shares of Lucid Diagnostics from $3.10 to $2.60 and set a “buy” rating for the company in a research note on Tuesday, March 14th.
Lucid Diagnostics Price Performance
Institutional Investors Weigh In On Lucid Diagnostics
Several institutional investors have recently made changes to their positions in the company. Luminus Management LLC lifted its holdings in Lucid Diagnostics by 15.7% during the 2nd quarter. Luminus Management LLC now owns 873,804 shares of the company’s stock valued at $1,975,000 after buying an additional 118,322 shares in the last quarter. Vanguard Group Inc. increased its position in Lucid Diagnostics by 11.3% during the 3rd quarter. Vanguard Group Inc. now owns 319,366 shares of the company’s stock valued at $489,000 after purchasing an additional 32,305 shares during the period. BlackRock Inc. increased its position in Lucid Diagnostics by 18.7% during the 1st quarter. BlackRock Inc. now owns 67,565 shares of the company’s stock valued at $227,000 after purchasing an additional 10,636 shares during the period. Geneos Wealth Management Inc. purchased a new position in Lucid Diagnostics during the 1st quarter valued at about $209,000. Finally, State Street Corp increased its position in Lucid Diagnostics by 24.4% during the 1st quarter. State Street Corp now owns 56,693 shares of the company’s stock valued at $190,000 after purchasing an additional 11,121 shares during the period. Institutional investors own 5.89% of the company’s stock.
Lucid Diagnostics Company Profile
Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.
- Get a free copy of the StockNews.com research report on Lucid Diagnostics (LUCD)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.